RNXT
RenovoRx, Inc.0.8427
-0.0974-10.4%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
30.88MP/E (TTM)
-Basic EPS (TTM)
-0.36Dividend Yield
0%Recent Filings
10-Q
Q2 FY2025 results
RenovoRx notched its first revenue quarter with $422K from RenovoCath sales in Q2 FY2025 ended June 30, up from zero a year ago while grossing 64% margins—yet operating losses narrowed to $2.7M from $3.0M y/y on steady R&D spend. YTD revenue hit $619K against $5.8M operating loss, widened from $5.5M last year amid manufacturing scale-up, but net loss eased to $5.3M from $3.5M thanks to $234K warrant fair-value gains. Cash swelled to $12.3M on $10.8M equity raise, funding TIGeR-PaC Phase III enrollment (95 patients, 61 events) and the new PanTheR registry—free cash flow turned negative at -$5.7M from operations minus $2K capex. No debt burdens; liquidity covers 12 months. Competition from established oncology therapies could crimp RenovoCath adoption.
8-K
RenovoRx Q2 revenue surges
RenovoRx posted $422,000 in Q2 2025 revenue from RenovoCath device sales, up from zero last year, with thirteen cancer centers now approved to buy—four already using it and reordering. The independent Data Monitoring Committee recommended continuing the Phase III TIGeR-PaC trial after interim review, keeping the team blinded to preserve FDA integrity. Cash stands at $12.3 million, funding operations through enrollment expected late this year or early next. Revenue growth signals demand, yet trial risks loom large.
8-K
Annual meeting approves directors, plan
RenovoRx stockholders approved the election of Shaun R. Bagai, Ramtin Agah, M.D., Kirsten Angela Macfarlane, Laurence J. Marton, M.D., Una S. Ryan, O.B.E., Ph.D., D.Sc., and Robert J. Spiegel, M.D., FACP as directors at the June 24, 2025 annual meeting, with terms expiring in 2026. They also ratified Frank, Rimerman + Co. LLP as auditors for 2025. The board approved amendments to the 2021 Omnibus Equity Incentive Plan, adding 913,794 shares and boosting the annual evergreen provision to 5% of outstanding shares. This bolsters governance continuity while expanding equity incentives for talent retention.
10-Q
Q1 FY2025 results
RenovoRx kicked off revenue generation with $197K from RenovoCath sales in Q1 FY2025 ended March 31, 2025, up from zero a year ago, though operating losses widened to $3.1M from $2.5M on higher R&D and SG&A spend for commercialization and the TIGeR-PaC trial. Net loss narrowed to $2.4M from $1.1M, thanks to a $584K gain on warrant liability fair value changes offsetting the prior $1.4M boost. Cash swelled to $14.6M after a $10.8M public offering, funding operations through late 2026 while free cash flow stayed negative at $3.4M used in operations minus $2K capex. No debt burdens, just a $935K warrant liability. The February offering added 11.5M shares, diluting but bolstering liquidity. Competition from established oncology players could crimp RenovoCath's early traction.
8-K
RenovoRx Q1 revenue surges
RenovoRx kicked off commercial sales of its FDA-cleared RenovoCath device, posting $200,000 in Q1 2025 revenue that beat expectations and sparked repeat orders from over ten institutions. Cash reserves hit $14.6 million, set to bankroll scaling up sales while pushing the Phase III TIGeR-PaC trial toward full enrollment and interim analysis in 2025. Yet trial outcomes remain uncertain amid regulatory hurdles.
GERN
Geron Corporation
1.34+0.01
GRTX
Galera Therapeutics, Inc.
0.02+0.00
LIXT
Lixte Biotechnology Holdings, I
4.10+0.11
NBTX
Nanobiotix S.A.
22.32+0.18
NUVB
Nuvation Bio Inc.
8.66+0.15
NVCT
Nuvectis Pharma, Inc.
7.69+0.04
RENB
Lunai Bioworks Inc.
1.42+0.00
RNTX
Rein Therapeutics, Inc.
1.35-0.13
SLNO
Soleno Therapeutics, Inc.
49.50-0.45
TOVX
Theriva Biologics, Inc.
0.21+0.01